Among the pro-tumoral activities of cancer-derived EVs is their potential to modulate glucose metabolism, a phenomenon that may be regulated by proteins of the glycolytic pathways carried by EVs, like PKM2, leading to enhanced cell proliferation and resistance to apoptosis of cancer cells, as shown by experiments with EVs of Triple-Negative breast cancer cell lines displaying high and low levels of glycolytic activity [187]. The gene discussed is PKM; the disease is breast carcinoma.